Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2016 Jun 28:9:201-5.
doi: 10.2147/DMSO.S99732. eCollection 2016.

Adherence to GLP-1 receptor agonist therapy administered by once-daily or once-weekly injection in patients with type 2 diabetes in Germany

Qing Qiao  1 , Mario Jnm Ouwens  1 , Susan Grandy  2 , Kristina Johnsson  1 , Karel Kostev  3
Affiliations

Adherence to GLP-1 receptor agonist therapy administered by once-daily or once-weekly injection in patients with type 2 diabetes in Germany

Qing Qiao et al. Diabetes Metab Syndr Obes. .

Abstract

Aim: This study aimed to compare 6-month adherence to therapy with exenatide once weekly (Bydureon(®)) vs liraglutide once daily (Victoza(®)) in patients with type 2 diabetes under primary care in Germany.

Methods: A nationwide longitudinal prescription database (LRx), (between January 2011 and September 2014) was used to analyze adherence to therapy. The proportion of days covered (PDC) by prescription was used as a measure of adherence in the 6-month postindex period. Logistic regression analyses were performed to investigate the associations between glucagon-like peptide-1 receptor agonist therapy adjusting for age, sex, and cotherapy.

Results: Therapy was initiated in 5,449 patients with exenatide once weekly (age: 59.7±11.8 years; 51.4% were male) and in 24,648 patients with liraglutide once daily (age: 59.4±11.4 years; 49.7% were male). The median PDC was 0.88 for exenatide once weekly and 0.77 for liraglutide once daily (P<0.05). Once-weekly exenatide was associated with significantly higher adherence. Odds ratio (95% confidence interval) for having a PDC of ≥0.80 was 1.78 (1.62-1.96) for exenatide once weekly compared with liraglutide once daily after adjusting for age, sex, and cotherapy.

Conclusion: Adherence to treatment with exenatide once weekly was significantly increased compared to that with liraglutide once daily over 6 months in patients with type 2 diabetes.

Keywords: GLP-1 receptor agonists; adherence; type 2 diabetes.

PubMed Disclaimer

Figures

Figure 1
Figure 1
Cumulative distribution of PDC values. Note: (A) Exenatide once weekly; (B) Liraglutide once daily. Abbreviation: PDC, proportion of days covered.
See this image and copyright information in PMC

References

    1. Holst JJ, Vilsboll T. Combining GLP-1 receptor agonists with insulin: therapeutic rationales and clinical findings. Diabetes Obes Metab. 2013;15(1):3–14. - PubMed
    1. Werner U. Effects of the GLP-1 receptor agonist lixisenatide on postprandial glucose and gastric emptying: preclinical evidence. J Diabetes Complications. 2014;28(1):110–114. - PubMed
    1. Garber AJ. Long-acting glucagon-like peptide 1 receptor agonists. A review of their efficacy and tolerability. Diabetes Care. 2011;34(suppl 2):S279–S284. - PMC - PubMed
    1. García-Pérez LE, Alvarez M, Dilla T, Gil-Guillén V, Orozco-Beltrán D. Adherence to therapies in patients with type 2 diabetes. Diabetes Ther. 2013;4(2):175–194. - PMC - PubMed
    1. Richter H, Dombrowski S, Hamer H, Hadji P, Kostev K. Use of a German longitudinal prescription database (LRx) in pharmacoepidemiology. Ger Med Sci. 2015;13:Doc14. - PMC - PubMed

LinkOut - more resources